Company news
Scynexis, Inc. news in 2019
Scynexis, Inc.'s news releases, calls and decks from 2019, newest first.
SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors
December 15, 2019
SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
December 11, 2019
SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants
December 9, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
November 11, 2019
SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
November 6, 2019
SCYNEXIS Announces Oral Presentation of Data from Ibrexafungerp Phase 2b DOVE Study at the 3rd ISIDOG Congress
October 30, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
October 23, 2019
SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program
October 9, 2019
SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
September 17, 2019
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
August 6, 2019
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
July 23, 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
June 13, 2019
SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
May 29, 2019
SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
April 30, 2019
SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
April 2, 2019